Taking the Myc out of cancer: toward therapeutic strategies to directly inhibit c-Myc

Abstract excerpt

c-Myc is a transcription factor that is constitutively and aberrantly expressed in over 70% of human cancers. Its direct inhibition has been shown to trigger rapid tumor regression in mice with only mild and fully reversible side effects, suggesting this to be a viable therapeutic strategy. Here we reassess the challenges of directly targeting c-Myc, evaluate lessons learned from current inhibitors, and explore...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Peptidase Inhibition and Analysis
• Share to Protein Degradation and Inhibitors
• Share to Ubiquitin and proteasome pathways